Loss-of-function mutations of cyclic-AMP response element binding protein, binding protein (CREBBP) are prevalent in lymphoid malignancies. However, the tumour suppressor functions of CREBBP remain unclear. We demonstrate that loss of Crebbp in murine haematopoietic stem and progenitor cells (HSPCs) leads to increased development of B-cell lymphomas. This is preceded by accumulation of hyperproliferative lymphoid progenitors with a defective DNA damage response (DDR) due to a failure to acetylate p53. We identify a premalignant lymphoma stem cell population with decreased H3K27ac, which undergoes transcriptional and genetic evolution due to the altered DDR, resulting in lymphomagenesis. Importantly, when Crebbp is lost later in lymphopoiesis, cellular abnormalities are lost and tumour generation is attenuated. We also document that CREBBP mutations may occur in HSPCs from patients with CREBBP-mutated lymphoma. These data suggest that earlier loss of Crebbp is advantageous for lymphoid transformation and inform the cellular origins and subsequent evolution of lymphoid malignancies.
The cyclic-AMP response element binding protein, binding protein CREBBP (also known as CBP and KAT3A) is a general transcriptional coactivator. CREBBP and its paralogue EP300 (also known as p300 and KAT3B) control processes during development and homeostasis through binding to multiple protein partners and acetylating lysine residues of histone (including H3K27Ac, H3K18Ac and H3K56Ac) and non-histone substrates 1 . Germline loss-offunction mutations of CREBBP in the Rubinstein-Taybi cancer predisposition syndrome suggested a tumour-suppressor role for CREBBP 2 , and early mouse models subsequently confirmed this 3 . More recently, somatic mutations, predominantly hemizygous and affecting the acetyltransferase domain, or deletions of CREBBP, have been described across a large number of sporadic tumours including myeloid haematological malignancies 4, 5 . However, CREBBP mutations are particularly frequent in both primitive and mature lymphoid malignancies, occurring in around 20% of relapsed B-cell acute lymphoblastic leukaemias (ALL) 6 , 40% of diffuse large B-cell lymphomas (DLBCL) 7 , 60% of follicular lymphomas (FL) 8 and also in T-ALL 9 and cutaneous T-cell lymphomas 10 . The mutations may occur throughout disease development, with variant allele frequency analysis demonstrating their very early acquisition in FL but longitudinal studies documenting their enrichment in relapsed ALL 6, 11, 12 . Despite this, the full extent of the function of CREBBP as a tumour suppressor and the reason for its predilection for the lymphoid lineage remain unanswered questions.
Many cancers are dependent on a population of stem or initiating cells for their continued growth and relapse, identifying a critical target population for therapeutic eradication 12 . However, for mature lymphoproliferative disorders (LPDs), such as lymphomas, although malignant stem cell populations are predicted, direct evidence for their existence is controversial 13 and, if present, their identity and provenance are mysterious. Moreover, the molecular and cellular perturbations that direct the evolution of this transformed cell towards a fully blown lymphoma remain entirely unknown. The target cell for transformation in mature lymphoid malignancies had previously been presumed to be a cell with inherent self-renewal and capable of antigenic memory 14, 15 . However, the demonstration of clonal human lymphopoietic reconstitution in murine xenotransplant recipients of haematopoietic stem and progenitor cell (HSPC) populations from chronic lymphocytic leukaemia (CLL) patients 16 and the existence of 'driver' mutations, such as BRAF and SF3B1 mutations, in HSPCs from hairy cell leukaemia (HCL) and CLL patients 17, 18 have challenged this hypothesis 19 .
In this study, we investigate the tumour suppressor functions of Crebbp in isolation and describe murine models with conditional inactivation of Crebbp at different stages of lymphopoiesis. Mice with early loss of Crebbp within the HSPC compartment demonstrate alterations of transcription, epigenetic regulation and DNA damage response (DDR) and an increased frequency of an aggressive LPD/lymphoma. This lymphoma is preceded by a distinct premalignant phase, allowing the interrogation of transcriptional, epigenetic and genetic events occurring during lymphoma evolution. In contrast, loss of Crebbp in committed lymphoid cells significantly abrogates the cellular phenotype and markedly reduces tumour development. Finally, we demonstrate the relevance of this for human disease, detecting a CREBBP mutation in the HSPC compartment of a patient whose lymphoma carried the same mutation. Taken together, these data have profound implications for the potential cellular origins and subsequent evolution of lymphoid malignancies.
RESULTS

Crebbp loss predisposes to an aggressive B-cell malignancy
Initially, we aged a cohort of mice where excision of Crebbp occurs within the HSPC compartment, following pIpC-mediated Mx1-Cre recombinase expression (hereafter Mx-Crebbp −/− mice) 20, 21 . Compared with wild-type littermate controls, Mx-Crebbp −/− mice displayed a significantly shorter survival ( Fig. 1a , P < 0.0001), with the incidence of haematological malignancies, particularly B-cell malignancies, more than doubled (accounting for 29% of all deaths, Fig. 1b and Supplementary Tables 1-3 ). These mice developed a longlatency aggressive LPD/lymphoma with predominantly blood and splenic involvement ( Fig. 1c,d ), although ∼10% also demonstrated lymphadenopathy. Tumour analysis revealed low-and high-grade morphology (Fig. 1d ), a mature surface phenotype (B220 + , CD19 + , sIgM + ), with aberrant expression of the B1-like markers Mac1 and CD5 (Fig. 1e) , and reflected aspects of human lymphoid malignancies associated with high frequencies of CREBBP mutations. The LPD also efficiently transferred disease to secondary recipients (Fig. 1f ).
Crebbp loss alters transcriptional and epigenetic regulation to change lymphoid progenitor function
We have previously shown that loss of Crebbp in HSPCs leads to stem and progenitor alterations, with a significant reduction of mature B and T cells apparent at later time points 21, 22 . At earlier time points (8-10 weeks post-pIpC), Mx-Crebbp −/− mice demonstrated a significant increase in lineage-negative cells (Lin − ) within bone marrow (BM) and peripheral blood (PB), with an increase of IL-7 receptor-α-positive (IL7Ra + ) progenitors in BM when compared with wild-type (WT) controls ( Fig. 2a,b ). Despite this, the frequency of common lymphoid progenitors (CLPs) and all downstream B-cell compartments including mature B-and T-cell populations were not altered at this time point ( Supplementary Fig. 1a-d) . This IL7Ra + compartment demonstrated lymphoid and limited myeloid potential in methylcellulose assays ( Fig. 2c and Supplementary  Fig. 1e ). Crebbp −/− IL7Ra + cells showed increased proliferation and clonogenic potential in lymphoid colony assays and enhanced selfrenewal when compared with WT controls ( Fig. 2c and Supplementary  Fig. 1e ). RNA-Seq analysis of this early IL7Ra + progenitor population revealed subtle differential gene expression between Mx-Crebbp −/− and WT mice ( Supplementary Table 4 ), with 97 genes including oncogenes Pbx3, Ets2, Yes1 and Yap1 upregulated and 101 genes including the lymphoid transcription factors and tumour-suppressor genes Tcf7 and Bcl11b, and the Notch inhibitor Dtx1 (ref. 23 ) downregulated ( Fig. 2d ). Gene set enrichment analysis (GSEA) demonstrated significant enrichment for genes differentially regulated in CREBBP mutant lymphomas 24 and also core embryonic stem cell, HSC and proliferation signatures ( Fig. 2e and Supplementary  Fig. 1f ). Genome-wide H3K27ac binding by ChIP-Seq revealed a larger number of differentially bound peaks; 416 peaks were downregulated from WT to Crebbp −/− progenitors, although only a small number of these overlapped with the downregulated genes (9/101, 10%) at this early time point ( Fig. 2f,g) . These data link Crebbp loss in the HSPC compartment with altered transcriptional and epigenetic regulation, disordered lymphoid differentiation and expansion of a hyperproliferative progenitor population with in vitro self-renewal potential.
Crebbp −/− progenitors acquire in vivo self-renewal and premalignant potential Serial analysis of PB in Mx-Crebbp −/− mice identified a population of aberrant lymphocytes, with a B220 + /Mac1 Int phenotype, similar to that observed in the overt LPD. This population was detected in the blood of every animal that succumbed to the disease, appearing as early as 10 weeks after pIpC administration and was often detectable many months prior to the development of disease ( Fig. 3a,b ). We hypothesized that this population was a premalignant ancestral population from which the overt lymphoma evolved and tested its stem cell properties in vivo. 'Premalignant' (PM) Mx-Crebbp −/− mice were identified by the presence of a B220 + Mac1 Int population and a normal white blood cell (WBC) count on PB testing, absence of clinical symptoms and a normal spleen weight following necropsy. The LSK population was isolated from the BM and the B220 + /Mac1 Int putative PM stem cell population was isolated from the spleen and were transplanted independently across a congenic background ( Fig. 3c ). Remarkably, highly efficient reconstitution (≥25% of PB) by the B220 + /Mac1 Int population was demonstrated in every recipient animal by four weeks (Fig. 3d left panel). In addition, this population expanded in vivo, and over a highly variable time course recipient animals developed an overt LPD indistinguishable from the disease in primary animals ( Fig. 3d right panel). Secondary transplantations performed using tumour cells from two recipient animals demonstrated a highly significant reduction in disease latency (median 48 versus 132 days, P = 0.0002) in keeping with evolution of the B220 + /Mac1 Int population to frankly malignant cells ( Fig. 3e ). 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 31 . Genotype-specific changes between Crebbp −/− and WT lymphomas were also evident, including downregulation of Pten and upregulation of Ccnd2. Tumours were demonstrated to be clonal by IgH analysis ( Supplementary Fig. 2 ). GSEA analysis showed enrichment for the CREBBP-mutant signature ( Fig. 4c ). CREBBP is known to acetylate multiple lysine residues on histones, with H3K27, H3K18 and H3K56 acetylation linked to transcription and DNA damage. We detected global loss of H3K27Ac in Crebbp −/− LPD compared with WT B220 + B cells ( Supplementary Fig. 3a ). ChIP-Seq at the Dtx1 locus demonstrates that downregulated gene expression is accompanied by a statistically significant loss of H3K27ac at an intragenic enhancer (boxed) in Crebbp −/− progenitors. All mice were treated with pIpC between 6 and 10 weeks after birth (7.7 weeks in a,b, 6.3 weeks in c and 6.9 weeks in d) and IL7Ra + cells were isolated from the BM 8-10 weeks (9.6 weeks in a,b, 8.1 weeks in c and 9 weeks in d) after pIpC administration.
We next performed genome-scale analysis of these modifications between Crebbp −/− LPD and WT B cells, as well as Crebbp binding in WT B cells, by ChIP-Seq. Although some loss of acetylation was demonstrated for all marks, this was most obvious for H3K27Ac, where 3,360 peaks showed decreased acetylation in Crebbp −/− lymphomas. Furthermore, H3K27Ac correlated best with Crebbp binding (Fig. 4d,e ) and with genes downregulated, where 1,308 of the differential H3K27Ac peaks were linked to a downregulated Supplementary Fig. 3b and Supplementary Tables  7-12 ). The majority of differential peaks were in enhancers rather than promoters, with both super-enhancers and normal enhancers dysregulated ( Fig. 4g,h) . De novo motif analysis of differentially bound peaks suggested altered regulation of transcriptional networks, including those regulated by Ets, Irf, Ebf and Mef2b transcription factors ( Fig. 4i ). We performed exome sequencing in 14 Crebbp −/− and all (n = 3) WT LPDs (Supplementary Tables 13-20) . Single-nucleotide variants (SNVs) and insertion/deletion events included recurrent alterations overlapping gene numbers are shown. (b) Volcano plot of differential gene expression between Mx-Crebbp −/− lymphomas (from n = 2 animals) and WT B220 cells (from n = 6 animals; B220 + cells from 3 WT animals pooled per sequencing reaction). The P value was generated using a negative binomial generalized linear model (DEseq2). (c) GSEA analysis of genes differentially expressed between Mx-Crebbp −/− and WT lymphomas demonstrates enrichment of a CREBBP-mutant human signature 24 in the Card11 and Gna13 genes and alteration of the Hist1h1d gene in a single case, all genes mutated in human lymphoma 8, 29 (Fig. 5a and Supplementary Fig. 4a ). Copy number analysis demonstrated recurrent losses and gains, including loss of the Cdkn2a and 2b locus, a common alteration in human lymphomas 32 . We also noted mutations in Ras-and Jak-Stat intermediates, pathways known to be activated in human lymphomas 7, 8, 33, 34 , and could demonstrate activation of these pathways in our Crebbp −/− and WT LPDs ( Supplementary  Fig. 4b ). Analysis of mutation patterns revealed predominantly C > T transitions and C > A transversions. Cosine analysis correlated this single signature best with human cancer signature 1 (ref. 35) ( Fig. 5b and Supplementary Fig. 4c,d) , which reflect the effects of ageing. Taken together, our data demonstrate transcriptional, epigenetic and genetic alterations within the Crebbp −/− lymphomas that overlap with human disease.
Crebbp modulates DNA damage and protects genomic integrity in lymphoid progenitors
Crebbp has been associated with DNA repair and the cellular response to DNA damage in a number of cell types 36 . This was also suggested by GSEA analysis of differential gene expression in Crebbp −/− progenitors ( Fig. 5c ) and we hypothesized that this might contribute to tumour evolution within the Crebbp −/− LPD. Therefore, we measured H2AX phosphorylation (H2AXγ foci), a surrogate for DNA double-stranded breaks, and the functional consequences of the DNA damage response (DDR) in IL7Ra + progenitors. At baseline we found no difference in H2AXγ foci between Mx-Crebbp −/− and WT mice. However, when dynamically induced with hydroxyurea (HU) treatment, DNA damage was significantly increased in Crebbp −/− mice ( Fig. 5d ,e, P = 0.047). However, surprisingly, given the degree of DNA damage, there was no expected increase in apoptosis in Crebbp −/− progenitors ( Fig. 5f ). Similarly, in colony-forming assays clonogenic potential and proliferation were almost fully preserved (Fig. 5g ). The DDR is orchestrated by p53, which in turn requires acetylation by p300 or Crebbp for its full transcriptional output 37, 38 . While WT mice demonstrated a brisk acetylation of p53 following DNA damage induction, none was evident for mice lacking Crebbp (Fig. 5h ). In addition, reduced induction of p53 target genes following DNA damage further demonstrated defective p53 activity ( Fig. 5i ). Collectively, these data suggest that loss of Crebbp abrogates optimal cellular response to DNA damage, with these subtle changes creating a permissive state for the retention and accumulation of subsequent mutations, facilitating transformation.
Evolution at the clonal idiotype, transcriptional and genetic levels in Crebbp −/− lymphomas The presence and accessibility of the B220 + /Mac1 Int premalignant stem cell population provided us with a unique opportunity to study the evolution of a mature lymphoid malignancy, as did comparisons between the premalignant donor cells and their lymphomatous progeny harvested from the transplant recipients in Fig. 3d . Using a next-generation sequencing method that we have developed 39 , we could demonstrate an early reduction in IgH diversity following Crebbp loss (Fig. 6a) . A further contraction of the IgH repertoire was evident following longitudinal analysis as the LPD/lymphoma developed in individual primary mice in vivo, as well as in transplant recipients of premalignant cells ( Fig. 6a-c ). Of note, in a small number of cases two IgH rearrangements were evident, and sequencing of RNA could demonstrate expression of both rearrangements in keeping with the transformation of multiple independent clones ( Fig. 6b ).
Comparing transcriptional changes across WT B cells, B220 + /Mac1 Int PM stem cells and Crebbp −/− lymphoma cells demonstrated significant transcriptional evolution (Fig. 6d,e and Supplementary Fig. 5a,b ). Only 469 and 587 genes were differentially regulated up and down respectively at this earlier time point between normal and PM cells ( Supplementary Table 21 ), compared with 3,546 and 3,071 genes respectively in the lymphomas ( Supplementary Table 22 ). These already included upregulation of Meis3 and multiple Hoxa and b paralogues as well as downregulation of multiple linker histone genes that are mutated in FL, including Hist1h1b and Hist1h1d. In addition, differential expression of 205/469 (44%) of upregulated genes and 88/587 (15%) of downregulated genes was also evident in the later lymphoma samples (Fig. 6e ).
Exome sequencing performed across lymphoma evolution in two Crebbp −/− LSK HSPC and eight premalignant B220 + /Mac1 Int stem cells also demonstrated evidence of genetic evolution when compared with both Crebbp −/− and WT lymphomas ( Fig. 6f ). This demonstrated a sequential increase in the average number of total mutations within these populations (P = 0.001 between the PM and the LPD), but no difference between Crebbp −/− and WT LPD. Exome data were available for the premalignant population transplanted, as well as 6 of the 7 tumours that developed in recipient mice in Fig. 3e . Comparisons of SNVs in the PM and subsequent tumours demonstrated significant divergent evolution; the transplanted PM cells contained only a single SNV (Cbx2); however, recipient tumours demonstrated variable numbers of SNVs (25-47, Supplementary Table 13 ), with only three SNVs common across all cases (Cbx2, Celf1 and Ceacam11, Fig. 6g ).
Loss of Crebbp in committed lymphoid cells attenuates disease generation and CREBBP mutations are present in patient HSPCs
The cellular phenotype observed following Crebbp deletion predominantly reads out in earlier lymphoid compartments. To assess whether the tumour suppressor functions of Crebbp were necessary at specific stages of lymphoid development and to identify the initial cell of transformation in our model, we generated a second mouse strain where Crebbp is deleted following lymphoid commitment, using a Cd19-Cre recombinase 40 (hereafter Cd19-Crebbp −/− ). Although there was no difference in the efficiency of recombination, we could find no differences in the size, composition or function of the HSPC compartment in Cd19-Crebbp −/− mice, in marked contrast to early loss of Crebbp ( Fig. 7a and Supplementary Fig. 6a-c) . Similarly, there was no difference in basal or induced DNA damage following HU treatment in the early compartment ( Fig. 7b ). Only the pro-B population was decreased when later lymphoid populations were examined ( Supplementary Fig. 6d,e ). Although the B220 + Mac1 Int population could be detected in Cd19-Crebbp −/− mice and occasional mice did develop B-cell LPD, no difference in survival was seen between Cd19-Crebbp −/− and WT mice and the number of B-cell LPDs, and other malignancies, was markedly reduced (Fig. 7c-e and Supplementary Fig. 6e and Supplementary  Tables 23-25 ). To determine the relevance of these findings for human disease, we screened the HSPC compartment of three patients 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190   2   0 10 20 30 40 50 60 70 80 90   10  0 110   12 0  13  0   14  0   150  160  170  180   3   0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150   4   0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150   5   0  10  20  30  40  50  60  70  80  90  100  110  120  130  140 ChIP-Seq and RNA-Seq at the critical gene X locus read out in terms of downregulation of gene expression only at later time points during lymphoma evolution. We speculate that the molecular aberrations cumulatively acquired interact with this primed epigenetic state and lead to the restoration of self-renewal in this abnormal premalignant stem cell population and to the evolution of lymphoma.
with CREBBP-mutated lymphoma (1 DLBCL and 2 FL) who lacked BM lymphoma involvement. HSPCs were flow-sorted and grown as colonies in methylcellulose under conditions that permitted only myeloid cell outgrowth and DNA was harvested (Fig. 7f ). Sensitive (∼1 mutant in 10 5 wild-type cells) bespoke forward and reverse allele-specific PCR assays were developed to screen for sentinel CREBBP mutations ( Supplementary Fig. 7a,b) . Although no evidence for a CREBBP mutation could be found in two patients, critically, in the remaining patient, the pathogenetic mutation (a 3-base-pair deletion leading to pS1608delS in the HAT domain) 7 identified in the tumour was also detected in the CD19 − /CD34 + /CD38 + HSPC compartment and confirmed by Sanger sequencing (Fig. 7g and Supplementary Fig. 7c,d) . These data demonstrate that early loss of Crebbp is advantageous for tumour formation in our model and that CREBBP mutations may occur in the HSPC compartment of patients with lymphoma.
DISCUSSION
CREBBP is mutated or deleted across a wide range of human cancers, identifying it as a generic tumour suppressor. In this report, we describe an increased frequency of a number of malignancies in Mx-Crebbp −/− mice, and further address the most common phenotype, that of mature B-cell malignancies. We mechanistically demonstrate specific loss of H3K27Ac that occurs early in lymphoid differentiation and progresses during the evolution of the lymphomas. Although these changes correlate poorly with downregulated genes in early premalignant progenitors, they and many more enhancers that lose H3K27Ac significantly correlate with later downregulated gene expression programs in overt lymphomas ( Supplementary Fig. 5b ). Of interest, although the acetylation and transcription alterations we report in our Crebbp −/− lymphomas mirror recent reports of murine models of follicular lymphomas where Crebbp loss or knockdown is combined with Bcl2 overexpression 31, 41 , differences are also apparent. In particular, we did not see any enrichment for Bcl6 targets by GSEA or de novo motif analysis at Crebbp-binding sites or sites with differential H3K27Ac, raising the possibility that loss of Crebbp collaborates with Bcl6 only in the context of Bcl2 overexpression.
We demonstrate that in the Mx1-Crebbp −/− mice, lymphoid progenitor populations accumulate, are hyperproliferative and demonstrate altered cellular responses to DNA damage following Crebbp deletion, which we link to the loss of post-translational activation of p53. This constellation of alterations cumulatively creates a 'perfect storm' for the acquisition (hyperproliferation) and retention (inefficient DDR) of mutations and we postulate that the 'primed' epigenetic state may also favour subsequent transformation by these mutations (see models in Fig. 7h ). CREBBP is a global transcriptional coactivator 42 that interacts with multiple master regulator transcription factors; therefore, it is likely that aspects of the tumour suppressor phenotype we describe in the context of lymphomagenesis also occur across a range of other tumours. However, lymphocytes are highly proliferative and undergo additional, significant endogenous physiological DNA damage, through antigen-receptor rearrangement and somatic hypermutation 14 . We suggest that our data defining a defective DDR provide a plausible explanation for the particularly high rates of CREBBP mutations in lymphoid malignancies.
Our model fits with the premise that loss of Crebbp predisposes to the subsequent development of mature lymphoid malignancies. This hypothesis would be in keeping with the observation that mutation or loss of CREBBP occurs across multiple lymphoma phenotypes. This would also fit with our description of Crebbp loss leading to the generation of a premalignant stem and progenitor population, with our model being, to our knowledge, the only one to demonstrate the existence of such a population for a mature lymphoid malignancy. Our study also sheds mechanistic light on the target of initial transformation in mature lymphoid malignancies. Early loss of Crebbp in the HSPC compartment resulted in a marked cellular phenotype and the development of an aggressive LPD. However, loss in a later, fully lymphoid-restricted compartment almost completely abrogated these abnormalities, significantly attenuating tumour formation. Moreover, we demonstrate that CREBBP mutations may occur in rigorously isolated HSPCs from patients with CREBBP-mutated lymphomas. A requirement for early loss of CREBBP function would be in keeping with phylogenetic sequencing studies in human follicular lymphoma, which show that CREBBP mutation occurs in the earliest inferable lymphoid progenitor 11, 12 , with the description of identical EP300 mutations in bone-marrow transplant donorrecipient pairs that both went on to develop lymphomas 43 and also with the identification that CREBBP mutations can rarely occur in HSPCs to cause age-related clonal haematopoiesis 44 . Furthermore, mutations of other clonal haematopoiesis genes TET2 and DNMT3A initially occurring in the HSPC compartment have been shown to generate predominantly T-cell lymphomas in some patients 45, 46 . Evidence from other mouse models would also be in keeping with events in earlier progenitor compartments contributing to the development of mature B-cell malignancies [47] [48] [49] . Moreover, it is increasingly apparent that for some human LPDs such as CLL and HCL, driver mutations such as BRAF V600E occur within phenotypic HSPCs [16] [17] [18] . Taken together, our murine and human data are therefore compatible with CREBBP mutations occurring throughout HSPC and later lymphoid ontogeny. Although the clinical relevance of this is currently unclear, it merits further investigation and it will be of interest to determine whether the first cell type in which the CREBBP mutation occurs as an initiating event has a bearing on the phenotype or clinical outcome of the lymphoma. Furthermore, our study models Crebbp loss, and it remains to be seen whether altered rather than reduced function, perhaps related to specific HAT domain mutants, contributes to lymphoma formation. Finally, our findings also provide a mechanistic explanation as to why acquisition of the same mutation earlier rather than later in differentiation would be advantageous for lymphoma development.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
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Mice. C57Bl6 Mx-Crebbp −/− (Crebbp FL/FL; Mx-Cre) conditional knockout mice and the induction of Cre-mediated recombination in these animals have been described previously 21 . To induce Cre-mediated recombination, 6-to 10-week-old Mx-Crebbp −/− and WT (Crebbp FL/FL; WT) mice were administered five doses of poly(I)·poly(C) (pIpC) (300 µg per dose; Sigma) by intraperitoneal injection every other day over ten days. All experiments were performed using littermates that were not selected for gender but age-matched in terms of date of birth and time of pIpC administration. CD19-Crebbp −/− (Crebbp FL/FL; CD19-Cre) conditional knockout mice were generated by breeding Crebbp FL/FL mice with CD19 Cre/+ transgenic mice, both on a C57BL/6 background. Deletion efficiency was determined in both cohorts by PCR of genomic DNA extracted from blood or spleen. Peripheral blood was collected and counted as described previously 21 . All mice were housed in an SPF animal facility and experiments were conducted under UK Home Office regulations. This research has been regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB). Power calculations were used to generate sample sizes. Randomization was genetic and the investigators were not blinded to group allocations. However, the animal technicians who delivered care and decided which animals needed to be euthanized were blinded.
Flow cytometry analysis.
Single-cell suspensions of bone-marrow (BM) cells and splenocytes were prepared as described previously 50 . All staining was performed in Dulbecco's phosphate-buffered saline (DPBS; Gibco Life Technologies) supplemented with 2% fetal bovine serum (FBS; Sigma) on ice. Cells were blocked using FcR blocking reagent (Miltenyi Biotech, 1:20) and stained with combinations of the antibodies listed in Supplementary Table 27 . Lymphoid progenitors were analysed using APC-mouse lineage antibody cocktail (558074, BD Biosciences), FITC anti-CD127 (IL7Ra), PE-Cy7 anti-c-Kit and PB anti-Sca1 ( Supplementary  Table 27 ). Dead cells were excluded by gating on 7AAD (420403, Biolegend)negative cells. Fluorescence-minus-one controls were used to set appropriate gates. Flow cytometry analysis were performed on a CyAn ADP flow cytometer (Dako) or an LSR Fortessa cell analyser (BD Biosciences) and data were analysed with FlowJo software v 10 (Tree Star).
Histopathology and immunohistochemistry. Tissues were fixed, embedded and sectioned as described previously 50 . Immunohistochemistry was performed using an autoimmunostainer with cover tile technology (Bond-III system, Leica Biosystems). The heat-induced antigen retrieval was performed using Bond Epitope Retrieval solution 2 (Leica Biosystems) for 30 min. Staining was performed using anti-Ki-67 (Abcam ab16667, clone SP6, 1:50) followed by biotin-SP-conjugated donkey antirabbit IgG (711-066-152; Jackson ImmunoResearch Laboratories) and Vectastain elite ABC kit (Vector labs, Pk-6100). The Bond Polymer Refine Detection kit (Leica, Biosystems) was used for visualization.
Isolation of murine cell populations by flow sorting.
Lin − CD45 + IL7Ra + populations were isolated from the BM of Mx-Crebbp −/− and WT mice 8-10 weeks after poly(I) · poly(C) treatment or from CD19-Crebbp −/− and WT mice 8-10 weeks after birth. Whole skeletons (except skull and ribs) were pooled and crushed from three animals of each genotype and resuspended in DPBS/2% FCS. Cells were filtered through a 70-µm cell strainer (BD Biosciences) and red blood cells (RBCs) were lysed using RBC lysis buffer (5 PRIME). Lineage-positive cells were depleted prior to sorting using the Easysep mouse haematopoietic progenitor cell enrichment kit (19756, Stem Cell Technologies). Lineage-depleted cells were stained with V500-streptavidin, CD45.2-FITC and CD127-PE-Cy7. CD45.2 was used to gate haematopoietic cells and 7AAD was used to exclude dead cells. The Lin − c-Kit + Sca1 + (LSK) and B220 + Mac1 int populations from the BM and spleens respectively of (pre)-malignant mice were isolated as follows. Lineage-depleted cells were prepared from the whole skeleton of individual premalignant mice as previously described. Cells were stained with V500-streptavidin, CD45.2-FITC, c-Kit-PE-Cy7 and Sca1-PB ( Supplementary Table 27 ). 7AAD was used to exclude dead cells. Total splenocytes were blocked and stained with B220-APC and CD11b-FITC. DAPI was used to exclude dead cells. All sorting was performed using an Influx cell sorter (BD Biosciences).
Isolation of human cell populations by flow sorting.
Bone-marrow samples from three patients with documented CREBBP mutations were thawed in DPBS/2% FCS and stained with CD34-APC, CD38-PE-Cy7 and CD19-FITC ( Supplementary  Table 27 ). Dead cells were excluded by gating on Zombie Aqua (423101, Biolegend)negative cells. Fluorescence-minus-one controls were used to set appropriate gates. CD34 + CD38 − CD19 − and CD34 + CD38 + CD19 − cells were sorted using a FACSAria III (BD Biosciences) and data analysed with FlowJo software (Tree Star). Cells were cultured in Methocult H4531 methylcellulose medium (StemCell Technologies) for seven days and DNA was extracted from the colonies. Informed consent was obtained from all patients and approved (UK IRAS, REC reference: 10/H0704/65, protocol number: 006650QM).
Two allele-specific PCRs were performed. Reaction 1; allele-specific forward primer 5 -CACTGGGAGTTCTCCTTGCG-3 and reverse primer 5 -ACAGGAT GCTTCGTCAGACC-3 , reaction 2; forward primer 5 -GACTAAAGCCCCTCC TCTCC-3 and allele-specific reverse primer 5 -GAGCGGCGCAAGGAGAAC-3 . PCR reactions contained 2.5 ng DNA, 400 nM of each primer and AmpliTaq Gold 360 DNA Polymerase. PCR conditions were as follows: a pre-denaturation of 95 • C for 10 min, 35 cycles of amplification for reaction 1 and 38 cycles for reaction 2 (95 • C for 20 s, 66 • C for 30 s and 72 • C for 30 s) and a final extension at 72 • C for 5 min. PCR products were separated on 10% polyacrylamide gel by electrophoresis and confirmed by Sanger sequencing analysis.
Transplantation assays. One million unfractionated (or B220 + Mac1 int sorted) splenocytes isolated from individual malignant mice were injected intravenously into sub-lethally (550 rads) or lethally irradiated (550 rads; 2 doses) C57BL/6 recipients. In other experiments, 1 × 10 6 B220 + Mac1 int sorted splenocytes isolated from individual premalignant mice or 8 × 10 3 -2 × 10 4 LSK cells were injected intravenously into lethally irradiated C57BL/6 congenic recipients (CD45.1). When recipients were lethally irradiated 2 × 10 5 -1 × 10 6 unfractionated CD45.1 + helper BM cells were mixed with the donor cells prior to injection. PB chimaerism was monitored monthly by flow cytometry analysis.
Serial replating assays. Lin − , CD45 + , IL7Ra + cells were plated in MethoCult M3630 methylcellulose medium (StemCell Technologies) supplemented with 100 ng ml −1 stem cell factor (SCF) and 10 ng ml −1 Flt3Ligand (Flt3L; Peprotech) to assess lymphoid potential or Methocult M3434 methylcellulose medium (StemCell Technologies) to assess myeloid potential. Cells were plated in duplicate and after seven days colonies were scored, pooled and identical numbers of cells were re-plated under the same conditions. RNA-Seq. Total RNA was extracted from Lin − CD45 + IL7Ra + cells isolated from Mx-Crebbp −/− and WT mice 8-10 weeks after poly(I) · poly (C) treatment using an RNeasy Plus Micro kit (Qiagen). In other experiments, RNA was extracted from unfractionated splenocytes of Mx-Crebbp −/− malignant mice (in which >80% of the cells were B220 + ) or sorted B220 + cells isolated from the splenocytes of WT mice using an RNeasy Plus mini kit (Qiagen). RNA quantity and quality was analysed by qubit and bioanalyser. Ribosomal RNA (rRNA) was depleted using a ribozero kit (Illumina) and purified with Qiagen RNA columns. For the WT versus malignant LPD comparison approximately 40-95 ng of depleted rRNA was used for library preparation using a Rapid Directional RNA-Seq Kit (5138-08 NEXTflex). Library quality was checked and 20 nm of each barcoded library was pooled together and sequenced at the CRUK Cambridge Institute genomics core (http://www.cruk.cam.ac.uk/core-facilities/genomics-core).
For the lymphoid progenitor comparison and premalignant (B220 + Mac1 + ) versus WT B220 + comparison, RNA libraries were generated from sorted cells using the Ovation Mouse RNA-Seq System (0348-32, NuGEN). Ribosomal RNA was then depleted with Insert Dependent Adapter Cleavage (InDA-C technology; NuGEN). Library quality was checked and then libraries were pooled in equimolar amounts prior to sequencing. All experiments were performed in duplicate on biologically independent samples.
RNA-Seq data analysis.
RNA-Seq reads were aligned to mouse genome (UCSC mm10) using RNA-Seq aligner STAR (version 2.4.0) (ref. 51 ) and the number of uniquely mapping reads was estimated using HTSeq-Count 52 and normalized as counts per million. Gene expression read counts were analysed to identify differentially expressed genes using DESeq2 (version 1.12.4) (ref. 53) after filtering genes with low read count. Features with adjusted P value <0.1 and absolute logarithmic (base 2) fold change >1 were considered as having significant altered expression. Differentially expressed genes were analysed for gene set enrichment using GSEA against a collection of gene sets and published information 54 .
ChIP-Seq. Lin − CD45 + IL7Ra + cells (lymphoid progenitors) were isolated from Mx-Crebbp −/− and WT mice 8-10 weeks after pIpC treatment. In other experiments, unfractionated splenocytes of Mx-Crebbp −/− malignant mice (in which >80% of the cells were B220 + ) or sorted B220 + cells isolated from the splenocytes of WT mice were used. Chromatin immunoprecipitation was performed with iDeal ChIP-Seq kits for Histones and Transcription Factors (Diagenode). In brief, 10 6 or 5 × 10 6 cells were crosslinked with 1% formaldehyde (Thermo Scientific) for 5 min (H3K27ac) or 15 min (Crebbp). Fixation was stopped using glycine (Fisher Scientific) and cells were washed twice with ice-cold PBS. Lysis buffer iL1 (or iL1b) and iL2 were used to prepare the nuclei pellets. Chromatin was sheared in Shearing buffer iS1 using the Bioruptor Plus (Diagenode) for 2-2.5 runs of 10 cycles (each cycle; 30 seconds DOI: 10.1038/ncb3597 'ON' and 45 s 'OFF') at high power setting. Immunoprecipitation mix was prepared by the addition of ChIP buffer iC1 (or iC1b), BSA, protease inhibitor cocktails, prewashed protein A-coated magnetic beads, antibody (1 µg for anti-H3K27ac antibody, ab4729, Abcam; 1 µg for anti-H3K56ac antibody, ab76307, Abcam; 1 µg for anti-H3K18ac antibody, ab1191, Abcam; 4 µg for anti-Crebbp antibody, sc-369, Santa Cruz) against the sheared chromatin and incubated at 4 • C overnight with rotation. Anti-Crebbp antibody was pre-incubated in the mix without sheared chromatin at 4 • C for 3-3.5 h prior to overnight incubation. Ten per cent of the sheared chromatins were kept aside as input samples. The next day, sequential washes of the chromatin-antibody-beads were performed with ice-cold Wash buffer iW1, iW2, iW3 and iW4 and the beads were captured on a magnetic rack. Elution buffer iE1 and iE2 were added to the beads and incubated at 65 • C for 4 h to elute and decrosslink the chromatin DNA. Finally, DNA was purified using QIAquick PCR Purification Kit (Qiagen) and eluted in 30 µl EB buffer. ChIP-Seq library preparation of ChIP DNA or input DNA was performed using TruSeq ChIP Sample Prep Kit (Illumina). Library DNA was quantified using KAPA Library Quantification Kit (Complete Kit (Universal) for Illumina platforms) (Kapa Biosystems) and library average size was determined by Agilent DNA 1000 Kit (Agilent Technologies) run on a 2100 Bioanalyser System (Agilent Technologies). Libraries were pooled for Single-Read 50 bp sequencing on an Illumina HiSeq 2500 or 4000 platform. Experiments were performed in duplicate on biologically independent samples apart from Crebbp in WT cells and H3K27Ac in IL7Ra + cells, which were performed once. Sample preparation for exome sequencing. LSK cells isolated from the BM of premalignant mice were expanded in MethoCult M3434 methylcellulose medium (StemCell technologies). After seven days, colonies were pooled and genomic DNA was extracted using a DNeasy blood and tissue kit (Qiagen). DNA was extracted from B220 + Mac1 int cells sorted from the spleens of premalignant mice using the same kit. Genomic DNA was isolated from unfractionated BM or spleen cells from malignant mice and tail tissue using a Puregene Core kit A (Qiagen).
ChIP
Sequencing metric and somatic variant calling section.
Whole-exome sequencing was performed using the Agilent whole-exome capture kit (SureSelect Mouse All Exon, http://www.genomics.agilent.com/article.jsp?pageId=3102&_ requestid=112619). Captured material was indexed and sequenced on the Illumina platform at the Wellcome Trust Sanger Institute. Raw pair end sequencing reads were aligned with BWA-mem to the GRCm38 mouse reference genome.
Aligned DNA sequence data from paired tumour/normal DNA samples were presented to the Cake pipeline, using the somatic variant callers Bambino, Mutect, SAMTools Mpileup, Somaticsniper and VarScan2. As described previously 58 , we used a somatic caller merging approach to identify somatic variants selecting only those detected by four or more of these algorithms for further analysis. Five of 27 tumours had matched germline DNA, and for the remaining tumours we used DNA from mice with the same background. Data were further filtered using a pool of germline variants generated by combining the calls from the five available matched normal samples. These calls were further refined by removing germline variants identified inhouse by the Wellcome Trust Sanger Institute Mouse Genome Project.
Mutation signature analysis. The mutational catalogue of somatic variants was interpreted using EMu, a probabilistic algorithm that infers the number of mutational processes operative in a tumour, and their individual signatures 59 . All somatic point mutations (including silent mutations) were mapped to the 96 possible trinucleotide combinations taking into account the opportunity of each mutation occurring in the context of each trinucleotide type within the mouse exome. We identified one statistically significant mutation signature; xC:G>T:Ax.
We also compared our catalogue of mouse mutation signatures against human cancer signatures 35 , after accounting for mutational opportunity. A cosine similarity analysis reveals that the xC:G>T:Ax has strongest correlation with human cancer signature 1.
BCR amplification and sequencing. Genomic DNA was extracted from RBC lysed peripheral blood samples using a KAPA Express Extract kit (KAPA Biosystems). DNA was extracted from malignant tissues as described previously. PCR amplification of ∼10 ng of DNA samples was performed with the JH reverse primers and the forward primer set pools (group 1 or group 2, 0.25 µM each), using 0.5 µl Phusion High-Fidelity DNA Polymerase (Finnzymes), 1 µl dNTPs (0.25 mM), 1 µl dithiothreitol (DTT) (0.25 mM), per 50 µl reaction. The following PCR program was used: 3 min at 94 • C, 40 cycles of 30 s at 94 • C, 15 s at 60 • C and 30 s at 72 • C, with a final extension cycle of 7 min at 72 • C on an MJ Thermocycler. Group 1 and group 2 primed products were pooled together for each sample. DNA was purified using QIAquick PCR Purification Kit (Qiagen) and eluted in 30 µl EB buffer. For each sample 1 µg DNA was used to prepare the sequencing library using TruSeq DNA PCR-Free Library Prep kit (Illumina) (starting from end-repairing onwards). Library DNA was quantified and multiplexed for Paired-End 300 bp sequencing on Illumina MiSeq platform. MiSeq reads were filtered for base quality (median >32) using QUASR 60 , and paired-end reads merged if they contained identical overlapping regions of >65 bp, or otherwise discarded. Non-immunoglobulin sequences were removed and only reads with significant similarity to reference IgHV genes in the IMGT database 61 by BLAST 62 were retained (<1 × 10 −10 E value). Primer sequences were trimmed from reads, and sequences retained for analysis only if both forward and reverse primer sequences were identified and sequence lengths were greater than 240 bp for MiSeq. The network generation algorithm and network properties were calculated as previously described 39 : each vertex represents a unique sequence, where relative vertex size is proportional to the number of identical reads. Edges join vertices that differ by single-nucleotide non-indel differences and clusters are collections of related, connected vertices. Mutational analysis was performed using IMGT/V-QUEST 63 .
Cell culture. No cell lines were used in this study. Lin − CD45 + IL7Ra + cells isolated from Mx-Crebbp −/− and WT mice 8-10 weeks after pIpC treatment or from Cd19-Cre and WT mice 8-10 weeks after birth were cultured overnight in Iscove's modified Dulbecco's medium supplemented with 5% FBS, 1% penicillin/streptomycin, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 2 mM glutamine and 50 µM 2-mercaptoethanol (all from Sigma) and 100 ng ml −1 SCF, 20 ng ml −1 interleukin-7 (IL-7) and 10 ng ml −1 Flt3L (Peprotech). In some experiments cells were cultured overnight with or without a low dose (100 µM) of hydroxyurea (HU; Sigma). For immunoblotting experiments, cells were counted the following morning and equal cell densities were cultured with 5 µM trichostatin A (TSA; Sigma) with or without 4 mM HU for 1 h. For quantitative real-time PCR (qRT-PCR) experiments cells were cultured with 4 mM HU for 4 h.
Immunofluorescence.
A maximum of 5 × 10 4 cells were adhered to poly-L-lysine (Sigma)-coated slides. Soluble and cytoskeletal proteins were removed using a modified pre-extraction protocol 64 . Slides were immersed in cytoskeleton buffer (10 mM PIPES (pH 6.8), 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA and 0.5% Triton X-100) for 5 min on ice and then cytoskeleton stripping buffer (10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl 2 , 1% Tween-40 and 0.5% sodium deoxycholate) for 5 min on ice. After washing with PBS on ice for 5 min, cells were fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature, permeabilized in 0.15% Triton X-100/PBS for 5 min at room temperature and blocked in 1% bovine serum albumin (BSA)/PBS overnight at 4 • C. Cells were stained with anti-phospho-histone H2AX (Ser139, Millipore, 05-636, clone JBM301, 1:500) for 1 h at 37 • C and then washed with PBS 3 × 5 min at room temperature. Cells were stained with Alexa Fluor 488 goat anti-mouse (ThermoFisher Scientific, R37120, 1:500) for 1 h at 37 • C, washed with PBS 3 × 5 min at room temperature and mounted with ProLong Gold mounting medium with DAPI (Invitrogen). A minimum of 100 cells were scored using a Zeiss AxioSkop 2 microscope and the number of phospho-H2AX foci per cell were recorded from three independent experiments. Images were acquired using a Zeiss AxioImager Z2 and processed in Zeiss ZEN software.
Apoptosis.
A maximum of 5 × 10 4 cells were adhered to poly-L-lysine (Sigma)coated slides and then apoptotic cells were detected using an In Situ Cell Death Detection kit, Fluorescein (Roche) according to the manufacturer's instructions. A minimum of 100 cells per condition were scored using a Zeiss AxioSkop 2 microscope.
Immunoblotting. Whole-cell lysates were prepared from 7 × 10 5 cells in 2× SDS-DTT sample buffer. Lysates were run on SDS-PAGE gels and transferred to PVDF membranes (Millipore) using standard protocols. Membranes were probed with the following primary antibodies at 1:1,000 dilution unless otherwise stated: acetyl-p53 Lys379 (1:500) (2570; Cell Signaling), total p53 (1C12; Cell Signaling), phospho-p44/42 MAPK (Erk1/2) Thr202/Tyr204 (9101; Cell Signaling), p44/42 MAPK (Erk1/2) (9102; Cell Signaling), phospho-Stat3 (Tyr705) (9131; Cell Signaling), Stat3 (79D7) (4904; Cell Signaling), histone H3 (acetyl K27) (ab4729, Abcam), histone H3 (ab1791, Abcam), beta actin (ab8227, Abcam). Membranes were probed with secondary antibodies conjugated to horseradish peroxidase (HRP) (GE Healthcare; 1:5,000) and proteins were detected using SuperSignal West Femto kit (Thermo Scientific).
